Patented Medicine Prices Review Board

Patented Medicine Prices Review Board
Name	Patented Medicine Prices Review Board
Formed	1987
Jurisdiction	Canada
Headquarters	Ottawa, Ontario

Patented Medicine Prices Review Board is a Canadian administrative tribunal and regulatory body created to oversee the pricing of patented pharmaceuticals in Canada. The board was established to implement provisions of federal legislation and to balance interests of Health Canada, Pharmaceutical Research and Manufacturers of America, Canadian Medical Association, Canadian Pharmacists Association, and provincial insurers such as Ontario Ministry of Health and Alberta Health Services. It operates within a legal and institutional ecosystem that includes the Supreme Court of Canada, the House of Commons of Canada, the Senate of Canada, and the Department of Justice (Canada).

History and Establishment

The board was created following debates in the Parliament of Canada and legislative negotiations involving stakeholders like the Canadian Life and Health Insurance Association, the Canadian Generic Pharmaceutical Association, and advocacy groups including Canadian Cancer Society, Cystic Fibrosis Canada, and the Canadian Diabetes Association. Its origins trace to amendments to the Patent Act (Canada) and the passage of the Patent Act provisions in the late 20th century, reflecting influences from international agreements such as the North American Free Trade Agreement and the World Trade Organization frameworks. Key political figures during formation included members of the Progressive Conservative Party of Canada and opposition parties such as the Liberal Party of Canada and the New Democratic Party (Canada), and legal challenges later reached appellate bodies like the Federal Court of Canada.

Mandate and Legal Framework

Statutory authority for the board derives from provisions enacted in federal statutes administered by the Minister of Health (Canada) and enforced through administrative law precedents from the Federal Court of Appeal and the Supreme Court of Canada. The mandate requires monitoring patented medicine prices, reporting to the Parliament of Canada, and ensuring compliance with the Patent Act pricing clauses while interacting with instruments like the Food and Drugs Act and regulatory agencies such as Health Canada. The board’s reporting obligations include annual reports tabled before the House of Commons of Canada and submissions considered by parliamentary committees including the House of Commons Standing Committee on Health.

Governance and Organizational Structure

Governance is vested in a chairperson and board members appointed by the Governor in Council on advice of the Prime Minister of Canada and the Minister of Health (Canada). Organizational units liaise with external stakeholders such as the Canadian Agency for Drugs and Technologies in Health, provincial formularies like British Columbia PharmaCare, and networks including the Canadian Institute for Health Information and the Canadian Agency for Drugs and Technologies in Health. Internal operations rely on legal counsel drawn from the Department of Justice (Canada), economists with connections to institutions like the University of Toronto, McGill University, and University of British Columbia, and policy analysts who interact with international counterparts such as the European Medicines Agency and the U.S. Food and Drug Administration.

Price Review and Compliance Processes

The board implements investigative and compliance procedures involving price reviews, excess profit calculations, and orders informed by comparative analyses using reference points such as prices in United States, United Kingdom, Germany, and France. Casework involves engagement with manufacturers represented by organizations like the Canadian Generic Pharmaceutical Association and multinational firms headquartered in cities such as Montreal, Toronto, and Vancouver. Enforcement tools include notices, voluntary compliance agreements, and referral mechanisms that have been litigated before the Federal Court of Canada and sometimes considered by the Supreme Court of Canada. The board’s methodologies draw on economic models developed in collaboration with academics from Queen’s University, Dalhousie University, and policy think tanks like the Fraser Institute and the Canadian Centre for Policy Alternatives.

Impact and Criticism

Scholars and interest groups including the Canadian Medical Association, Canadian Pharmacists Association, Canadian Nurses Association, and patient advocacy organizations such as Heart and Stroke Foundation of Canada have debated the board’s role in controlling costs versus fostering pharmaceutical innovation credited to companies like Pfizer, GlaxoSmithKline, Novartis, and Roche. Critics from the Canadian Federation of Independent Business and commentators in media outlets based in Toronto, Ottawa, and Vancouver have argued about effectiveness and transparency, prompting reviews by bodies like the Office of the Auditor General of Canada and parliamentary panels including the Senate of Canada Committee on Social Affairs, Science and Technology. Supporters highlight contributions to provincial drug plan sustainability observed in programs like Ontario Drug Benefit and national spending analyses by the Canadian Institute for Health Information.

Notable Cases and Decisions

Notable enforcement matters have involved major pharmaceutical firms with global operations in markets such as United States, European Union, and Japan, resulting in orders, administrative settlements, or judicial review before tribunals such as the Federal Court of Canada and appeals considered by the Supreme Court of Canada. High-profile decisions referenced by policymakers, academics at McMaster University and commentators from the Globe and Mail and National Post have shaped debates on pricing methodologies, international price comparisons, and the interplay with patent law adjudicated under the Patent Act (Canada). Several cases prompted testimony before the House of Commons Standing Committee on Health and reviews by provincial ministries including Quebec Ministry of Health and Social Services and Manitoba Health, Seniors and Active Living.

Category:Federal departments and agencies of Canada